Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of ...

Treatment with esketamine combined with an SNRI is linked to fewer adverse outcomes than treatment with an SSRI alone.

Pharmaceutical companies cannot patent generic ketamine for depression, but Janssen, a subsidiary of Johnson & Johnson, patented esketamine, which it named Spravato. The cost of the two drugs ...

A drug inspired by the anesthetic ketamine just became the first new kind of depression medication in 35 years. Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson ...

Johnson & Johnson is to press on with filings for its new depression drug, esketamine, despite one of two late-stage studies missing an efficacy target. Ketamine is best known as an anaesthetic ...

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" under medical supervision and has a prescription from "an actual, real doctor." ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one roof would be ideal.

Janssen’s potential depression treatment made from esketamine – a version of the substance notoriously used illegally as a party drug – is to be reviewed by advisers to the FDA at a crunch ...

Two cutting edge treatments for though-to-treat major depression are remarkably successful: TMS Therapy and Spravato (Esketamine) treatment. TMS is safe, medication free and covered by insurance.

Esketamine Market: Revolutionizing Treatment-Resistant Depression The esketamine market is experiencing significant growth, driven by the urgent need for effective treatments for treatment ...

As we honor Counseling Awareness Month,�Relief Mental Health recognizes the critical role that therapy plays in helping individuals navigate mental health challenges and build a life worth living.